摘要
目的 观察二甲双胍和吡格列酮加用诺和锐30R治疗2型糖尿病的临床疗效.方法 选取105例长期口服二甲双胍或吡格列酮,之前未用过胰岛素且血糖控制不理想的2型糖尿病患者,在受试前4周调整二甲双胍或吡格列酮剂量为FBG6.5～7.5mmol/L,PBG-2h 8～10mmol/L.然后随机分为两组,一组继续口服二甲双胍或吡格列酮,另一组在口服药的基础上于早餐和晚餐前加用诺和锐30R,治疗12周.观察患者FBG、PBG-2h及HbA1c的达标率.结果 两组患者治疗12周后,加用诺和锐30R组患者的FBG、PBG-2h值明显低于对照组,HbA1c的达标率明显高于对照组,两组相比差异有统计学意义.结论 对口服二甲双胍或吡格列酮治疗疗效不佳的2型糖尿病患者,在口服药基础上加用诺和锐30R能使患者血糖得到良好控制.
Objective To investigate the clinical efficacy of pioglitazone and metformin plus Insulin Aspart 30 Injection for treating type 2 diabetes. Methods To choose 105 cases of type 2 diabetes patients with long-term oral metformin or pioglitazone,never inject insulin and glycemic control is not satisfactory. To adjust the dosage of metformin or pioglitazone four weeks before the test. FBG was 6.5-7.5 mmol/L,PBG-2h 8-10 mmol/L. They were randomly divided into two groups. The first group continued to have oral metformin or pioglitazone. The second group received Insulin Aspart 30 Injection on basis of the oral medication before breakfast and dinner for 12 weeks. To observe FBG, PBC--2h and HbAlc target rate. Results After 12 weeks of treatment. The second group patientsr FBG, PBG-2h were significantly lower than those of the control group, HbA1c＇s target rate was significantly higher than that of the control group. There was statistical difference between the two groups. Conclusion Adding Insulin Aspart 30 Injection on basis of the oral medication to those type 2 diabetic patients, who has oral pioglitazone or metformin but the efficacy is not apparent,can make good control of blood glucose.
出处
《重庆医学》
CAS
CSCD
2007年第18期1861-1862,共2页
Chongqing medicine
